ES2877583T3 - Procedimiento para producir (4S)-4-[4-ciano-2-(metilsulfonil)fenil]-3,6-dimetil-2-oxo-1-[3-(trifluorometil)fenil]-1,2,3,4-tetrahidropirimidin-5-carbonitrilo - Google Patents
Procedimiento para producir (4S)-4-[4-ciano-2-(metilsulfonil)fenil]-3,6-dimetil-2-oxo-1-[3-(trifluorometil)fenil]-1,2,3,4-tetrahidropirimidin-5-carbonitrilo Download PDFInfo
- Publication number
- ES2877583T3 ES2877583T3 ES16713747T ES16713747T ES2877583T3 ES 2877583 T3 ES2877583 T3 ES 2877583T3 ES 16713747 T ES16713747 T ES 16713747T ES 16713747 T ES16713747 T ES 16713747T ES 2877583 T3 ES2877583 T3 ES 2877583T3
- Authority
- ES
- Spain
- Prior art keywords
- formula
- compound
- give
- subsequently
- reaction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 CC([C@]1*)C(C)=C=C1C(F)(F)F Chemical compound CC([C@]1*)C(C)=C=C1C(F)(F)F 0.000 description 5
- PKEQRLCWKDDNML-FIPDIQNESA-N CC(N(c1cc(C(F)(F)F)ccc1)C(N(C)[C@@H]1c(c(S(C)(=C)=O)c2)ccc2C#N)=O)=C1C(OCC=C)=O Chemical compound CC(N(c1cc(C(F)(F)F)ccc1)C(N(C)[C@@H]1c(c(S(C)(=C)=O)c2)ccc2C#N)=O)=C1C(OCC=C)=O PKEQRLCWKDDNML-FIPDIQNESA-N 0.000 description 1
- YAJWYFPMASPAMM-HXUWFJFHSA-N CC(N(c1cc(C(F)(F)F)ccc1)C(N(C)[C@@H]1c(c(S(C)(=O)=O)c2)ccc2C#N)=O)=C1C#N Chemical compound CC(N(c1cc(C(F)(F)F)ccc1)C(N(C)[C@@H]1c(c(S(C)(=O)=O)c2)ccc2C#N)=O)=C1C#N YAJWYFPMASPAMM-HXUWFJFHSA-N 0.000 description 1
- NABLENYIVPZWGZ-LJQANCHMSA-N CC(N(c1cc(C(F)(F)F)ccc1)C(N(C)[C@@H]1c(c(S(C)(=O)=O)c2)ccc2C#N)=O)=C1C(N)=O Chemical compound CC(N(c1cc(C(F)(F)F)ccc1)C(N(C)[C@@H]1c(c(S(C)(=O)=O)c2)ccc2C#N)=O)=C1C(N)=O NABLENYIVPZWGZ-LJQANCHMSA-N 0.000 description 1
- OBTQYBNHHLMLID-UHFFFAOYSA-N CC(N(c1cc(C(F)(F)F)ccc1)C(NC1c(c(S(C)(=O)=O)c2)ccc2C#N)=O)=C1C(OCC=C)=O Chemical compound CC(N(c1cc(C(F)(F)F)ccc1)C(NC1c(c(S(C)(=O)=O)c2)ccc2C#N)=O)=C1C(OCC=C)=O OBTQYBNHHLMLID-UHFFFAOYSA-N 0.000 description 1
- MVDRIMBGRZBWPE-UHFFFAOYSA-N Cc1ccc(C=O)c(F)c1 Chemical compound Cc1ccc(C=O)c(F)c1 MVDRIMBGRZBWPE-UHFFFAOYSA-N 0.000 description 1
- QXHUSGWCFSXQMF-UHFFFAOYSA-N N#Cc1ccc(C=O)c(F)c1 Chemical compound N#Cc1ccc(C=O)c(F)c1 QXHUSGWCFSXQMF-UHFFFAOYSA-N 0.000 description 1
- HLWWJWCYZFXALP-UHFFFAOYSA-N NC(NC1=CC(C(F)(F)F)=CCC1)=O Chemical compound NC(NC1=CC(C(F)(F)F)=CCC1)=O HLWWJWCYZFXALP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/20—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D239/22—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C315/00—Preparation of sulfones; Preparation of sulfoxides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15159570 | 2015-03-18 | ||
| PCT/EP2016/055498 WO2016146607A1 (de) | 2015-03-18 | 2016-03-15 | Verfahren zur herstellung von (4s)-4-[4-cyano-2-(methylsulfonyl)phenyl]-3,6-dimethyl-2-oxo-1-[3-(trifluormethyl)phenyl]-1,2,3,4-tetrahydro pyrimidin-5-carbonitril |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2877583T3 true ES2877583T3 (es) | 2021-11-17 |
Family
ID=52684127
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES16713747T Active ES2877583T3 (es) | 2015-03-18 | 2016-03-15 | Procedimiento para producir (4S)-4-[4-ciano-2-(metilsulfonil)fenil]-3,6-dimetil-2-oxo-1-[3-(trifluorometil)fenil]-1,2,3,4-tetrahidropirimidin-5-carbonitrilo |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US10316001B2 (enExample) |
| EP (1) | EP3271337B1 (enExample) |
| JP (4) | JP7390100B2 (enExample) |
| KR (1) | KR20170129191A (enExample) |
| CN (2) | CN107635972A (enExample) |
| AU (1) | AU2016232270B2 (enExample) |
| CA (1) | CA2980071A1 (enExample) |
| ES (1) | ES2877583T3 (enExample) |
| WO (1) | WO2016146607A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2980071A1 (en) | 2015-03-18 | 2016-09-22 | Bayer Pharma Aktiengesellschaft | Method for preparation of (4s)-4-[4-cyano-2-(methylsulfonyl)phenyl]-3,6-dimethyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydro pyrimidine-5-carbonitrile |
| KR20210002573A (ko) | 2018-04-24 | 2021-01-08 | 주식회사 피에이치파마 | 간 질환에 호중구 엘라스타제 저해제의 사용 |
| CA3151997A1 (en) * | 2019-08-23 | 2021-03-04 | Ph Pharma Co., Ltd. | Use of a neutrophil elastase inhibitor in lung disease |
| CN112304919B (zh) * | 2020-09-18 | 2022-07-05 | 公安部物证鉴定中心 | 一种乌头碱类植物毒素的定性定量检测方法 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9214053D0 (en) | 1992-07-02 | 1992-08-12 | Ici Plc | Heterocyclic amides |
| US6372936B1 (en) * | 1999-06-09 | 2002-04-16 | Eli Lilly And Company | Optical resolution of aminoisobobutyric acid |
| MY125533A (en) | 1999-12-06 | 2006-08-30 | Bristol Myers Squibb Co | Heterocyclic dihydropyrimidine compounds |
| GB0219896D0 (en) | 2002-08-27 | 2002-10-02 | Bayer Ag | Dihydropyridine derivatives |
| GB0220962D0 (en) * | 2002-09-10 | 2002-10-23 | Bayer Ag | Heterocyclic derivatives |
| CA2498052C (en) | 2002-09-10 | 2011-05-17 | Bayer Healthcare Ag | Heterocyclic derivatives |
| MXPA05002644A (es) | 2002-09-10 | 2005-09-20 | Bayer Healthcare Ag | Derivados de pirimidinona como agentes terapeuticos contra procesos de remodelacion, isquemicos e inflamatorios agudos y cronicos. |
| US20060079554A1 (en) | 2002-12-06 | 2006-04-13 | Barry Peter C | Inhibitors of monomine uptake |
| US7166603B2 (en) | 2003-07-23 | 2007-01-23 | Bristol-Myers Squibb Co. | Dihydropyrimidone inhibitors of calcium channel function |
| ES2394177T3 (es) * | 2004-02-26 | 2013-01-23 | Bayer Intellectual Property Gmbh | 1,4-diaril-dihidropirimidin-2-onas y su uso como inhibidores de elastasa de neutrófilos humanos |
| JP4825195B2 (ja) | 2004-02-26 | 2011-11-30 | バイエル・シェーリング・ファルマ・アクチェンゲゼルシャフト | １，４−ジアリール−ジヒドロピリミジン−２オン化合物およびヒト好中球エラスターゼ阻害剤としてのそれらの使用 |
| GB0502258D0 (en) | 2005-02-03 | 2005-03-09 | Argenta Discovery Ltd | Compounds and their use |
| GB0512940D0 (en) | 2005-06-24 | 2005-08-03 | Argenta Discovery Ltd | Compounds and their use |
| GB0520743D0 (en) | 2005-10-12 | 2005-11-23 | Argenta Discovery Ltd | Compounds and their use |
| AU2006321947A1 (en) * | 2005-12-05 | 2007-06-14 | Wyeth | Process for preparing substituted aryl cycloalkanol derivatives |
| DK2024367T3 (da) | 2006-05-04 | 2011-01-03 | Pulmagen Therapeutics Inflammation Ltd | Tetrahydropyrrolopyrimidindioner og deres anvendelse som inhibitorer af human neutrofil elastase |
| US20100010024A1 (en) | 2006-07-01 | 2010-01-14 | Bayer Healthcare Ag | Use of1,4-diaryl-dihydropyrimidine-2-on derivatives for treating pulmonary arterial hypertension |
| US20110003858A1 (en) | 2006-09-04 | 2011-01-06 | Bergstroem Lena | Multimeric heterocyclic compounds useful as neutrophil elastase inhibitors |
| DE102008022521A1 (de) | 2008-05-07 | 2009-11-12 | Bayer Schering Pharma Aktiengesellschaft | 1,4-Diaryl-pyrimidopyridazin-2,5-dione und ihre Verwendung |
| HRP20120457T1 (hr) | 2007-12-20 | 2012-06-30 | Bayer Pharma Aktiengesellschaft | 4-(4-cijano-2-tioaril)dihidropirimidinoni i njihova uporaba |
| DE102009016553A1 (de) | 2009-04-06 | 2010-10-07 | Bayer Schering Pharma Aktiengesellschaft | Sulfonamid- und Sulfoximin-substituierte Diaryldihydropyrimidinone und ihre Verwendung |
| CA2980071A1 (en) | 2015-03-18 | 2016-09-22 | Bayer Pharma Aktiengesellschaft | Method for preparation of (4s)-4-[4-cyano-2-(methylsulfonyl)phenyl]-3,6-dimethyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydro pyrimidine-5-carbonitrile |
-
2016
- 2016-03-15 CA CA2980071A patent/CA2980071A1/en active Pending
- 2016-03-15 ES ES16713747T patent/ES2877583T3/es active Active
- 2016-03-15 JP JP2017549057A patent/JP7390100B2/ja active Active
- 2016-03-15 EP EP16713747.0A patent/EP3271337B1/de active Active
- 2016-03-15 AU AU2016232270A patent/AU2016232270B2/en not_active Ceased
- 2016-03-15 KR KR1020177029441A patent/KR20170129191A/ko not_active Ceased
- 2016-03-15 CN CN201680028214.7A patent/CN107635972A/zh active Pending
- 2016-03-15 WO PCT/EP2016/055498 patent/WO2016146607A1/de not_active Ceased
- 2016-03-15 US US15/559,385 patent/US10316001B2/en active Active
- 2016-03-15 CN CN201911315571.3A patent/CN110981815A/zh active Pending
-
2019
- 2019-04-25 US US16/394,811 patent/US10676443B2/en active Active
-
2020
- 2020-07-03 JP JP2020115899A patent/JP7125450B2/ja not_active Expired - Fee Related
-
2021
- 2021-05-12 JP JP2021081100A patent/JP7117415B2/ja not_active Expired - Fee Related
-
2022
- 2022-08-12 JP JP2022128861A patent/JP2022145951A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20170129191A (ko) | 2017-11-24 |
| EP3271337B1 (de) | 2021-03-03 |
| CA2980071A1 (en) | 2016-09-22 |
| EP3271337A1 (de) | 2018-01-24 |
| JP7125450B2 (ja) | 2022-08-24 |
| CN107635972A (zh) | 2018-01-26 |
| JP2018508549A (ja) | 2018-03-29 |
| US20180072685A1 (en) | 2018-03-15 |
| JP7117415B2 (ja) | 2022-08-12 |
| US10676443B2 (en) | 2020-06-09 |
| JP2020172529A (ja) | 2020-10-22 |
| WO2016146607A1 (de) | 2016-09-22 |
| AU2016232270B2 (en) | 2020-09-03 |
| US10316001B2 (en) | 2019-06-11 |
| JP2021138711A (ja) | 2021-09-16 |
| JP7390100B2 (ja) | 2023-12-01 |
| CN110981815A (zh) | 2020-04-10 |
| JP2022145951A (ja) | 2022-10-04 |
| US20190248750A1 (en) | 2019-08-15 |
| AU2016232270A1 (en) | 2017-10-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN108314639B (zh) | 化合物（e）-3-（1-甲基吡咯烷-2-基）-丙烯酸盐酸盐及合成方法 | |
| JP7117415B2 (ja) | （４ｓ）－４－［４－シアノ－２－（メチルスルホニル）フェニル］－３，６－ジメチル－２－オキソ－１－［３－（トリフルオロメチル）フェニル］－１，２，３，４－テトラヒドロピリミジン－５－カルボニトリルの製造方法 | |
| JP2014524920A5 (enExample) | ||
| ES2633838T3 (es) | Método para preparar derivados tricíclicos | |
| JP5921556B2 (ja) | （３ｓ，３ｓ’）４，４’−ジスルファンジイルビス（３−アミノブタン−１−スルホン酸）を調製する方法 | |
| CN112154140B (zh) | 化合物及其在合成布瓦西坦(Brivaracetam)原料药中的用途 | |
| KR20140013232A (ko) | Ｎ-(2-히드록시에틸)니코틴아미드 및 니코란딜의 제조방법 | |
| JP2023062038A (ja) | ガドブトロールの製造方法 | |
| CN102911160A (zh) | 一种制备和纯化达比加群酯中间体的方法 | |
| CN103435526B (zh) | 一种维达列汀的合成方法 | |
| ES2452940T3 (es) | Procedimiento novedoso de preparación de base de imatinib | |
| CN114845991B (zh) | 合成美法仑的方法 | |
| CN112920053B (zh) | 一种手性α-甲基芳乙胺的制备方法 | |
| CN103012261B (zh) | 一种孟鲁司特钠及其中间体的制备方法 | |
| CN103450069A (zh) | 一种米格列奈钙的制备方法 | |
| CN103242220B (zh) | 丁酸氯维地平的制备方法 | |
| CN102659657B (zh) | 一种蛋白酶抑制剂pf429242的合成方法 | |
| HK40019597A (en) | Method for producing compounds | |
| JP7279134B2 (ja) | プロリンアミド化合物の製造方法 | |
| CN103408542A (zh) | 一种高纯度的达沙替尼无水物的制备方法 | |
| CN110790731A (zh) | 4取代-γ丁内酯的制备方法 | |
| EP4725944A1 (en) | New method for preparing oxopyridine compound, and key intermediate and use | |
| CN119462661A (zh) | 一种azd-8421及其中间体的制备方法 | |
| CN103232429B (zh) | (e)-n-[3-(甲氨基)丙基]-3-(噻吩-2-基)丙烯酰胺及其盐的制备方法 | |
| CN119059990A (zh) | 1-氨基甲酸叔丁酯哌嗪的制备方法 |